Biobanking Market to Surpass USD 206.61 Billion by 2035 | SNS Insider

The U.S. biobanking market is forecast to rise from $35.71B in 2025 to $66.92B by 2035, while Europe is expected to grow from $26.99B to $59.57B over the same period. Growth is attributed to expanding genomics research, precision medicine programs, and increased biorepository investment. Overall, the outlook signals a favorable medium-term demand tailwind for the sector.

Analysis

This reads less like a discrete end-market call and more like a multi-year demand signal for the picks-and-shovels layer of life sciences. The economic value should accrue disproportionately to vendors with recurring consumables, automation, and installed-base service revenue, while standalone biobank operators risk being trapped in a low-margin storage and logistics business. In practice, the best public-market expressions are likely Thermo Fisher and Danaher, not because they "own biobanking," but because they monetize the workflow around sample collection, preservation, tracking, and downstream assay throughput.

Near term, the market may underreact because this is a budget-cycle story, not a same-quarter revenue catalyst. The real driver is whether national precision-medicine programs and pharma-sponsored sample banks translate into capex and reagent orders over the next 3-6 quarters; if they do, order growth should show up first in instruments/software, then in consumables with a lag. A softer NIH/European funding backdrop or delayed hospital capex would be the main falsifier, especially if management commentary in TMO/DHR/A starts referencing longer sales cycles.

The contrarian miss is that TAM growth does not automatically mean pricing power: as storage scales, cost per sample falls, which can compress economics for pure-play repository businesses even while sample counts rise. That argues for favoring the enablers over the custodians and for skepticism toward any thesis that assumes linear revenue conversion from "more biobanking." Over 6-18 months, the bigger beneficiary could be data/workflow standardization, where lab software and automation lower switching costs and lock in recurring spend.

Key Decisions for Investors

• Long TMO and DHR on pullbacks over the next 1-3 months; use these as higher-quality expressions of the biobanking/precision-medicine cycle, with a 6-18 month horizon and better margin durability than pure-play storage operators.
• Pair trade: long TMO / short ILMN for the next 3-6 months to express "workflow monetization beats sample-volume optimism"; ILMN has more execution and funding sensitivity, while TMO captures broader consumables/service pull-through.
• Avoid chasing any biobank-only or repository-heavy names until there is evidence of operating leverage; this theme is more likely to create vendor winners than durable standalone platform winners.
• Set an alert on NIH/EU research funding and hospital capex commentary in upcoming earnings cycles; a negative revision there would invalidate the thesis and argue for reducing life-science-tool exposure.